Beyond the Status Quo: Particulate Matter Standards in Oral Dosage Forms

Particulate contamination in oral dosage forms poses significant challenges to product integrity and patient trust, yet these formulations lack the well-defined regulatory limits established for injectables. This review comprehensively analyses existing literature, regulatory guidelines, and analytical techniques to identify primary contamination sources, assess regulatory gaps, and propose science-based mitigation strategies. Key contamination vectors include raw materials, manufacturing equipment, facilities, packaging, personnel activities, utilities, processing aids, cleaning residues, and process design deficiencies. While solid oral dosage forms can encapsulate particulates, liquid formulations present a heightened ingestion risk. To combat these vulnerabilities, advanced analytical techniques—such as Fourier transform infrared spectroscopy, Raman spectroscopy, scanning electron microscopy with energy-dispersive X-ray spectroscopy, and X-ray fluorescence—are evaluated alongside emerging artificial intelligence-driven detection and real-time monitoring systems. Because current regulations inadequately address particulate matter in oral dosage forms, this paper introduces a structured decision pathway model to enhance contamination management. Ultimately, regulatory harmonization is essential for patient safety, and future research must focus on refining detection methodologies, risk-based strategies and establishing scientifically justified particulate thresholds.